Clinical Trial: Signet Ring Cell Carcinoma in Esophageal Adenocarcinoma

Study Status: Completed
Recruit Status: Completed
Study Type: Observational

Official Title: Signet Ring Cells in Esophageal and GE Junction Carcinomas Have a More Aggressive Biological Behavior

Brief Summary: There has been much controversy surrounding the biologic behavior and prognosis of esophageal signet ring cell (SRCs) containing carcinomas. To clarify the biologic behavior of SRCs, the investigators compared the clinicopathologic features and prognosis of SRCs with other adenocarcinomas (ADC) of the esophagus and gastroesophageal junction (GEJ).

Detailed Summary:

Adenocarcinoma (ADC) of the esophagus and gastroesophageal junction (GEJ) is an aggressive neoplasm and has a poor prognosis. Surgical based treatment has been the treatment of choice for localized esophageal adenocarcinoma.

Signet-ring cell carcinoma is a unique histologic subtype of adenocarcinoma characterized by abundant intracellular mucin accumulation and a compressed nucleus displaced toward one extremity of the cell (the so-called signet-ring cell (SRC)). According to the World Health Organisation (WHO), a true signet-ring cell carcinoma (SRCca) is defined as an adenocarcinoma in which the predominant component (more than 50% of the tumor) consists of isolated or small groups of SRC in the stroma. If the tumor contains less than 50% of those cells, it is generally considered as an adenocarcinoma (ADC).


Sponsor: University Hospital, Gasthuisberg

Current Primary Outcome: Cancer specific 5 year survival in SRCC [ Time Frame: from surgery ]

Cancer specific 5 year survival classified into two groups according to WHO criteria (>50% SRC or <50% SRC)


Original Primary Outcome: Same as current

Current Secondary Outcome:

Original Secondary Outcome:

Information By: University Hospital, Gasthuisberg

Dates:
Date Received: April 2, 2013
Date Started: March 2012
Date Completion:
Last Updated: April 4, 2013
Last Verified: April 2013